Description

FLIBAN 100 MG

Indications

FLIBAN 100 MG is primarily indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by a persistent lack of sexual desire that causes marked distress or interpersonal difficulty. FLIBAN is intended for use in women who have not experienced a satisfactory response to non-pharmacological interventions and who are not on any contraindicated medications.

Mechanism of Action

FLIBAN, also known as flibanserin, acts as a selective serotonin receptor modulator. It primarily targets the 5-HT1A and 5-HT2A serotonin receptors in the brain. By enhancing the release of dopamine and norepinephrine while inhibiting serotonin release, FLIBAN helps to restore sexual desire and arousal in women with HSDD. This dual action is thought to balance the neurotransmitters involved in sexual function, thereby improving sexual desire.

Pharmacological Properties

FLIBAN is classified as a non-hormonal treatment for sexual dysfunction. It is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 0.5 to 4 hours. The drug has a half-life of approximately 11 hours, which allows for once-daily dosing. FLIBAN undergoes extensive hepatic metabolism, primarily by the cytochrome P450 enzyme CYP3A4, which is crucial for its pharmacokinetics. The drug is primarily excreted in urine, with a small percentage eliminated in feces.

Contraindications

FLIBAN is contraindicated in patients with a known hypersensitivity to flibanserin or any of its components. It should not be used in conjunction with alcohol due to the risk of severe hypotension and syncope. Additionally, FLIBAN is contraindicated in patients with liver impairment, as well as those taking strong CYP3A4 inhibitors, such as ketoconazole or certain HIV protease inhibitors, due to the potential for increased drug levels and toxicity.

Side Effects

The most common side effects associated with FLIBAN include dizziness, nausea, fatigue, insomnia, and dry mouth. These side effects are generally mild to moderate in intensity. Serious adverse events, such as hypotension or syncope, may occur, particularly when FLIBAN is taken with alcohol or other central nervous system depressants. It is important for patients to be aware of these potential side effects and to report any severe or persistent symptoms to their healthcare provider.

Dosage and Administration

The recommended dosage of FLIBAN is 100 mg taken orally once daily at bedtime. It is important to take FLIBAN consistently at the same time each day to maintain stable drug levels in the body. Patients should be advised to avoid alcohol consumption while on FLIBAN therapy, as this can significantly increase the risk of severe side effects. If a dose is missed, patients should take it as soon as they remember, but they should not double the dose if it is close to the time of the next scheduled dose.

Interactions

FLIBAN has several significant drug interactions that must be considered. The most notable interactions occur with alcohol, which can lead to severe hypotension and syncope. Strong CYP3A4 inhibitors, such as ketoconazole and certain antiretroviral medications, can increase the plasma concentration of FLIBAN, leading to an increased risk of side effects. Conversely, strong CYP3A4 inducers, such as rifampin, can decrease the effectiveness of FLIBAN. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Before initiating treatment with FLIBAN, healthcare providers should conduct a thorough assessment of the patient’s medical history and current medications. Special caution should be exercised in patients with a history of depression or other mood disorders, as FLIBAN may exacerbate these conditions. Regular follow-up appointments are recommended to monitor the patient’s response to treatment and to adjust the dosage if necessary. Patients should also be educated about the signs of hypotension and advised to seek medical attention if they experience symptoms such as lightheadedness or fainting.

Clinical Studies

Clinical studies have demonstrated the efficacy of FLIBAN in improving sexual desire and reducing distress associated with HSDD. In randomized, double-blind, placebo-controlled trials, women taking FLIBAN reported a significant increase in the number of satisfying sexual events compared to those receiving placebo. Additionally, improvements in sexual desire scores were observed, indicating a positive impact on sexual function. The safety profile of FLIBAN was consistent with the reported side effects, and the drug was generally well tolerated among participants.

Conclusion

FLIBAN 100 MG represents a novel approach to the treatment of hypoactive sexual desire disorder in premenopausal women. By targeting specific neurotransmitter systems in the brain, FLIBAN can help restore sexual desire and improve quality of life for women affected by this condition. As with any medication, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure safe and effective use. Patients should engage in open discussions with their healthcare providers to determine if FLIBAN is an appropriate treatment option for their individual needs.